Neogenomics Inc is a leading provider of cancer-focused genetic testing and diagnostic services. The company specializes in developing advanced technologies that enhance the accuracy of cancer diagnosis and treatment planning. Through its comprehensive suite of laboratory services, Neogenomics aids healthcare providers by offering insights into genetic markers associated with various cancers, enabling personalized medicine approaches. In addition to its testing services, Neogenomics is dedicated to research and development, striving to improve and innovate methodologies that contribute to better patient outcomes in oncology. Read More
The stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO)
jumped 22.5% in the morning session after a court ruled in the company's favor in a patent infringement lawsuit against Natera.
NeoGenomics wins a North Carolina court ruling invalidating key Natera patents, clearing the way for its RaDaR ST assay and boosting investor sentiment.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the District Court for the Middle District of North Carolina has granted NeoGenomics’ motion for summary judgment that all of Natera’s asserted patent claims are invalid for claiming ineligible subject matter. The Court stated that it will dismiss Natera’s claims against NeoGenomics with prejudice and enter declaratory judgment of invalidity of both of Natera’s asserted patents.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 3.1%. This performance is a noticeable divergence from the S&P 500’s 10.3% return.
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q2, starting with NeoGenomics (NASDAQ:NEO).
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 10.2% year on year to $181.3 million. The company’s full-year revenue guidance of $723 million at the midpoint came in 2.9% below analysts’ estimates. Its non-GAAP profit of $0.03 per share was in line with analysts’ consensus estimates.
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO)
jumped 4.8% in the afternoon session after news of a significant insider purchase by a key executive. The move followed the disclosure of an insider purchase by Jeffrey Sherman, the Chief Financial Officer of a company subsidiary. Sherman acquired 20,000 shares, a transaction often interpreted by investors as a strong signal of confidence in a company's prospects. This positive development appeared to outweigh the more cautious sentiment from Wall Street, where a consensus of analysts rated the stock as a "Hold." Investors seemingly focused on the executive's bullish action rather than recent negative headlines, including a law firm's investigation into the company's prior financial reporting.
